Retinai

RetinAI is a healthcare software company focused on ophthalmology, and its platform, RetinAI Discovery, combines medical data management with automatic AI analysis. It collects imaging and clinical data in one place, harmonizes it, and analyzes it at scale to extract insights about disease progression, treatment outcomes and progression prediction. Discovery accepts DICOM compliant and proprietary formats and provides secure, cloud based access for collaboration across clinical, medical and digital teams. The company serves four groups: pharma and life sciences, clinics and hospitals, clinical and academic researchers, and academic AI researchers. Use cases include research and development, large clinical studies and real world evidence collection, and development and validation of clinical decision support tools or AI companion diagnostics. Related products include RetinAI OCT Atlas, announced as CE marked for clinical use with one algorithm for AMD, diabetic retinopathy, diabetic macular edema and glaucoma, and LuxIA, a diabetic retinopathy screening algorithm co developed with FVS that holds CE MDR certification. The vendor reports that Discovery has CE marking as a Class IIa medical device under the EU Medical Devices Regulation and has received FDA clearance. RetinAI U.S. Inc. is a subsidiary of Ikerian AG. The site publishes no pricing. Interested organizations are directed to request a demo or get started through the contact route.